Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

  • Zhu, Lucia
  • Retana, Diana
  • García Gómez, Pedro
  • Álvaro Espinosa, Laura
  • Priego, Neibla
  • Masmudi Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández Encinas, Elena
  • Blanco Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, María Jesús
  • Ortega Paino, Eva
  • Torres Ruiz, Raúl
  • Rodríguez Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González León, Pedro
  • Jiménez Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez Núñez, Ángel
  • Hernández Laín, Aurelio
  • Toldos, Óscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández Alen, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Vareslija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cusso Mula, Lorena
  • Desco Menéndez, Manuel
  • Mourón, Silvana
  • Quintela Fandino, Miguel
  • Weller, Michael
  • Pastor, Joaquín
  • Valiente, Manuel
We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood-brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere., Ministerio de Economía, Industria y Competitividad, Gobierno de España (MINECO). Grant Numbers: SAF2017-89643-R, SAF2014-57243-R, SAF2015-62547-ERC, RYC-2013-13365 FERO. Grant Number: IX FERO Grant for Research in Oncology Fundació la Marató de TV3 (TV3 Marathon Foundation). Grant Number: 141 Melanoma Research Alliance (MRA). Grant Number: 498103 Beug Foundation. Grant Number: Prize for Metastasis Research 2017 Fundación Ramón Areces (Ramón Areces Foundation). Grant Numbers: CIVP19S8163, CIVP20S10662 Worldwide Cancer Research (WCR). Grant Number: 19-0177 H2020-FETOPEN. Grant Number: 828972 Cancer Research Institute (CRI). Grant Number: 54545 Fundación Científica Asociación Española Contra el Cáncer (AECC). Grant Numbers: GCTRA16015SEOA, LABAE19002VALI, POSTD19016PRIE EC | H2020 | H2020 Priority Excellent Science | H2020 European Research Council (ERC). Grant Number: 864759 Sophien-Stiftung zur Förderung der klinischen Krebsforschung Stiftung fur angewandte Krebsforschung Forschungskredit of the University of Zurich. Grant Number: FK-18-054 Betty and David Koetser Foundation for Brain Research Comunidad de Madrid (Community of Madrid). Grant Numbers: S2017/BMD-3867 RENIM-CM, Y2018/NMT-4949 NanoLiver-CM MEC | Instituto de Salud Carlos III (ISCIII). Grant Number: PT20/00044 Ministero dellIstruzione, dellUniversita e della Ricerca-MIUR. Grant Number: D15D18000410001 Science Foundation Ireland Frontiers for the Future Award. Grant Number: 19/FFP/6443 Science Foundation Ireland Strategic Partnership Programme, Precision Oncology Ireland. Grant Number: 18/SPP/3522 Breast Cancer Now. Grant Number: 2019AugSF1310 La Caixa-Severo Ochoa International PhD Program Fellowship. Grant Number: LCF/BQ/SO16/52270014 La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie. Grant Number: LCF/BQ/DI17/11620028 Boehringer Ingelheim Fonds MD fellowship European Molecular Biology Organization. Grant Number: 4053 Foundation for Applied Cancer Research in Zurich
Repisalud
Publicación Artículo científico (JournalArticle)

Brain Microenvironment Heterogeneity: Potential Value for Brain Tumors.

  • Álvaro-Espinosa, Laura
  • de Pablos-Aragoneses, Ana
  • Valiente, Manuel
  • Priego, Neibla
Uncovering the complexity of the microenvironment that emerges in brain disorders is key to identify potential vulnerabilities that might help challenging diseases affecting this organ. Recently, genomic and proteomic analyses, especially at the single cell level, have reported previously unrecognized diversity within brain cell types. The complexity of the brain microenvironment increases during disease partly due to the immune infiltration from the periphery that contributes to redefine the brain connectome by establishing a new crosstalk with resident brain cell types. Within the rewired brain ecosystem, glial cell subpopulations are emerging hubs modulating the dialogue between the Immune System and the Central Nervous System with important consequences in the progression of brain tumors and other disorders. Single cell technologies are crucial not only to define and track the origin of disease-associated cell types, but also to identify their molecular similarities and differences that might be linked to specific brain injuries. These altered molecular patterns derived from reprogramming the healthy brain into an injured organ, might provide a new generation of therapeutic targets to challenge highly prevalent and lethal brain disorders that remain incurable with unprecedented specificity and limited toxicities. In this perspective, we present the most relevant clinical and pre-clinical work regarding the characterization of the heterogeneity within different components of the microenvironment in the healthy and injured brain with a special interest on single cell analysis. Finally, we discuss how understanding the diversity of the brain microenvironment could be exploited for translational purposes, particularly in primary and secondary tumors affecting the brain.
Repisalud
Publicación Artículo científico (JournalArticle)

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

  • Monteiro, Cátia
  • Miarka, Lauritz
  • Perea-García, María
  • Priego, Neibla
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • de Pablos-Aragoneses, Ana
  • Yebra, Natalia
  • Retana, Diana
  • Baena, Patricia
  • Fustero-Torre, Coral
  • Graña-Castro, Osvaldo
  • Troulé, Kevin
  • Caleiras, Eduardo
  • Tezanos, Patricia
  • Muela, Pablo
  • Cintado, Elisa
  • Trejo, José Luis
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Mazarico Gallego, José
  • Ferrer, Irene
  • Suárez, Rocío
  • Garrido-Martín, Eva M
  • Paz-Ares, Luis
  • Dalmasso, Celine
  • Cohen-Jonathan Moyal, Elizabeth
  • Siegfried, Aurore
  • Hegarty, Aisling
  • Keelan, Stephen
  • Varešlija, Damir
  • Young, Leonie S
  • Mohme, Malte
  • Goy, Yvonne
  • Wikman, Harriet
  • Fernández-Alén, Jose
  • Blasco, Guillermo
  • Alcázar, Lucía
  • Cabañuz, Clara
  • Grivennikov, Sergei I
  • Ianus, Andrada
  • Shemesh, Noam
  • Faria, Claudia C
  • Lee, Rebecca
  • Lorigan, Paul
  • Le Rhun, Emilie
  • Weller, Michael
  • Soffietti, Riccardo
  • Bertero, Luca
  • Ricardi, Umberto
  • Bosch-Barrera, Joaquim
  • Sais, Elia
  • Teixidor, Eduard
  • Hernández-Martínez, Alejandro
  • Calvo, Alfonso
  • Aristu, Javier
  • Martin, Santiago M
  • Gonzalez, Alvaro
  • Adler, Omer
  • Erez, Neta
  • Valiente, Manuel
  • Monteiro, Cátia
  • Miarka, Lauritz
  • Perea-García, María
  • Priego, Neibla
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • de Pablos-Aragoneses, Ana
  • Yebra, Natalia
  • Retana, Diana
  • Baena, Patricia
  • Fustero-Torre, Coral
  • Graña-Castro, Osvaldo
  • Troulé, Kevin
  • Caleiras, Eduardo
  • Tezanos, Patricia
  • Muela, Pablo
  • Cintado, Elisa
  • Trejo, José Luis
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Lain, Aurelio
  • Mazarico Gallego, José
  • Ferrer, Irene
  • Suárez, Rocío
  • Garrido-Martín, Eva M
  • Paz-Ares, Luis
  • Dalmasso, Celine
  • Cohen-Jonathan Moyal, Elizabeth
  • Siegfried, Aurore
  • Hegarty, Aisling
  • Keelan, Stephen
  • Varešlija, Damir
  • Young, Leonie S
  • Mohme, Malte
  • Goy, Yvonne
  • Wikman, Harriet
  • Fernández-Alén, Jose
  • Blasco, Guillermo
  • Alcázar, Lucía
  • Cabañuz, Clara
  • Grivennikov, Sergei I
  • Ianus, Andrada
  • Shemesh, Noam
  • Faria, Claudia C
  • Lee, Rebecca
  • Lorigan, Paul
  • Le Rhun, Emilie
  • Weller, Michael
  • Soffietti, Riccardo
  • Bertero, Luca
  • Ricardi, Umberto
  • Bosch-Barrera, Joaquim
  • Sais, Elia
  • Teixidor, Eduard
  • Hernández-Martínez, Alejandro
  • Calvo, Alfonso
  • Aristu, Javier
  • Martin, Santiago M
  • Gonzalez, Alvaro
  • Adler, Omer
  • Erez, Neta
Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9-RAGE-NF-κB-JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.
Repisalud
Publicación Artículo científico (JournalArticle)

Animal models of brain metastasis.

  • Miarka, Lauritz
  • Valiente, Manuel
Modeling of metastatic disease in animal models is a critical resource to study the complexity of this multi-step process in a relevant system. Available models of metastatic disease to the brain are still far from ideal but they allow to address specific aspects of the biology or mimic clinically relevant scenarios. We not only review experimental models and their potential improvements but also discuss specific answers that could be obtained from them on unsolved aspects of clinical management.
Repisalud
Publicación Artículo científico antes de ser publicado, versión del autor (Preprint)

Brain metastasis models: What should we aim to achieve better treatments?

  • Masmudi-Martín, M
  • Zhu, L
  • Sanchez-Navarro, M
  • Priego, N
  • Casanova-Acebes, M
  • Giralt, E
  • Masmudi-Martín, M.
  • Zhu, L.
  • Sanchez-Navarro, M.
  • Priego, N.
  • Casanova-Acebes, M.
  • Ruiz-Rodado, V
  • Giralt, E.
  • Valiente, Manuel
Brain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders

  • Alvaro-Espinosa, Laura
  • Marquez-Galera, Angel
  • Priego, Neibla
  • García-Calvo, Virginia
  • Perea-García, Maria
  • Hernandez-Oliver, Carolina
  • Retana, Diana
  • Sanchez, Oliva
  • Pablos-Aragoneses, Ana de
  • García-Gómez, Pedro
  • Graña-Castro, Osvaldo
  • Lapuente-Santana, Óscar
  • Serrano-Ron, Laura
  • Al-Shahrour, Fatima
  • Cayuela López, Ana
  • Peset, Isabel
  • Megías, Diego
  • Ola, Mihaela
  • Varešlija, Damir
  • Young, Leonie S.
  • Martí-Mateos, Yolanda
  • Enríquez, Jose A.
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Soengas, María S.
  • Bernhagen, Juergen
  • Antón-Fernández, Alejandro
  • Ávila, Jesús
  • Marchena, Miguel A.
  • Torres, Maximiliano
  • Castro Soubriet, Fernando de
  • Márquez-Ropero, Mar
  • Sierra, Amanda
  • López-Atalaya, José P.
  • Valiente, Manuel
  • RENACER Group
The upregulation of CD74, a chaperone involved in MHC-II antigen processing, has been mostly interpreted as indicative of antigen presentation in multiple brain disorders. However, CD74 expression has also been described in cancer cells across multiple tumor types and in the tumor microenvironment, notably in glioma. In this study, we found that the presence of CD74+ microglia/macrophages, which was induced by increased levels of interferon γ in brains affected by metastases, did not relate to its canonical pathway. Instead, the alternative function of CD74 as a cytokine receptor was pivotal. Proliferating cancer cells produced high levels of the ligand migration inhibitory factor (MIF) that bound the CD74 receptor and induced its translocation to the nucleus where it activated an NF-κB-dependent program that promoted metastatic progression. In patients, a CD74 signature was associated with more aggressive progression of brain metastatic disease, although it had no clinical correlation with the matched primary tumor. Interestingly, a pan-disease noncanonical and clinically relevant signature derived from the CD74+ myeloid population was identified that occurred in additional brain disorders, including Alzheimer's disease and multiple sclerosis. The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases and possibly other brain disorders., We thank all members of the Brain Metastasis Group for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Estefanía Sánchez-Jiménez (F. de Castro laboratory at Instituto Cajal-CSIC) and the staff at the Animal Facilities of the Instituto Cajal-CSIC for their extraordinary help with animals of the cuprizone demyelinating murine model of multiple sclerosis. Special thanks to patients and their families who donated valuable materials to RENACER and all site personnel, investigators, funders, and industry partners who supported the generation of the data within this study. Postmortem cortical brain tissue blocks from patients with multiple sclerosis and controls, as well as the associated clinical and neuropathologic data, were supplied by the Multiple Sclerosis & Parkinson’s Tissue Bank at Imperial College (London, United Kingdom), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207495. We thank J. Massagué (MSKCC) for some of the BrM cell lines. This study was funded by La Marató (201906-30-31-32; M. Valiente), MICIU (SAF2017-89643-R, SAF2014-57243-R, and SAF2015-62547-ERC to M. Valiente; PID2022-143110OB-I00 and RED2024-153909-E to F. de Castro), H2020-FETOPEN (828972; M. Valiente), Bristol Myers Squibb MRA Young Investigator Award (498103; M. Valiente), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018; 54545; M. Valiente), LAB AECC 2019 (LABAE19002VALI; M. Valiente), AECC Coordinados (PRYCO234528VALI; M. Valiente), ERC CoG (864759; M. Valiente), and ERANET-TRANSCAN-3 (TRANSCAN2021-203; M. Valiente) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI), CaixaResearch Health (HR23-00051; M. Valiente), MINECO-Ramón y Cajal (RYC-2013-13365; M. Valiente), MICIU/AEI/10.13039/501100011033 and ERDF (RTI2018-102260-B-I00; J.P. Lopez-Atalaya), Generalitat Valenciana (PROMETEO/2020/007; J.P. Lopez-Atalaya), Ramón Areces Foundation (CIVP20S10662 to E. Ortega-Paino/M.-J. Artiga; CIVP19S8163 to M. Valiente; and CIVP19A5917 to F. de Castro), Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (RTI2018-099267-B-I00 and PID2022-136698OB-I00; A. Sierra), Basque Government grants (IT1473-22; A. Sierra), Alzheimer Association award (AARG-NTF-24-1304352; A. Sierra), Breast Cancer Ireland (18239A01; L.S. Young), Research Ireland (19/FFP/6443; L.S. Young, 20/FFP-P/8597; D. Varešlija, and 23/SPP/11783; L.S. Young, D. Varešlija), Breast Cancer Now (2021 July PCC1460; L.S. Young, D. Varešlija, 2019 Aug SF1310 with the generous support of Walk the Walk; D. Varešlija), MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia, PRTR (RTI2018-099357-B-I00, PID2021-1279880B, and TED2021-131611B-I00; J.A. Enríquez), CIBERFES (CB16/10/00282; J.A. Enríquez), Foundation Leducq (17CVD04; J.A. Enríquez), MCIN/AEI/10 PID2023-147213OB-I00 (M.S. Soengas), ERC-Advanced Grant 884699 (M.S. Soengas), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028; P. García-Gómez and LCF/BQ/DI19/11730044; A. de Pablos-Aragoneses), AECC postdoctoral fellowship (POSTD19016PRIE; N. Priego), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995; L. Alvaro-Espinosa), FPI-Severo Ochoa Fellowship PRE2018-083478 awarded by MICIU/AEI/10.13039/501100011033, and European Social Funds (FSE invierte en tu futuro; Y. Martí-Mateos). M. Valiente is an EMBO YIP member (4053). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S funded by MCIU/AEI/10.13039/501100011033). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and is a Severo Ochoa Center of Excellence (SEV-2015-0510)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed